Dyve Biosciences

1 follower

Dyve is a clinical-stage biotech company with its lead asset, DYV700, currently completing a 20-center, 100-patient, Phase 2 clinical study for the treatment of acute gout.

Industries

Employees

11-50

Links


Org chart

Co-founder & CEO
CEO

Board & advisors

Executive Chairman
Chief Scientific Officer
Board Member
Board Member
Board Member